A Phase III Clinical Study of the Efficacy and Safety of Botulinum Toxin Type A (MASPORT) with DYSPORT for the Treatment of Glabellar Lines
ConclusionAbobotulinum toxin A [MASPORT] is equally safe and effective as commercial product [DYSPORT] for the treatment of glabellar lines with the dose of 50 units, up to 120 days.Level of Evidence IThis journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authorswww.springer.com/00266. (Source: Aesthetic Plastic Surgery)
Source: Aesthetic Plastic Surgery - January 17, 2024 Category: Cosmetic Surgery Source Type: research
Management of primary plantar hyperhidrosis with botulinum toxin type A: A retrospective case series of 129 patients
CONCLUSIONS: The results of this retrospective study suggest that BoNT-A is an effective and safe treatment option for PPH.PMID:37964488 | DOI:10.1111/ajd.14188 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - November 15, 2023 Category: Dermatology Authors: Aikaterini Tsiogka Efthymia Agiasofitou Antonios Tsimpidakis George Kontochristopoulos Alexander Stratigos Stamatios Gregoriou Source Type: research
Management of primary plantar hyperhidrosis with botulinum toxin type A: A retrospective case series of 129 patients
CONCLUSIONS: The results of this retrospective study suggest that BoNT-A is an effective and safe treatment option for PPH.PMID:37964488 | DOI:10.1111/ajd.14188 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - November 15, 2023 Category: Dermatology Authors: Aikaterini Tsiogka Efthymia Agiasofitou Antonios Tsimpidakis George Kontochristopoulos Alexander Stratigos Stamatios Gregoriou Source Type: research
Management of primary plantar hyperhidrosis with botulinum toxin type A: A retrospective case series of 129 patients
CONCLUSIONS: The results of this retrospective study suggest that BoNT-A is an effective and safe treatment option for PPH.PMID:37964488 | DOI:10.1111/ajd.14188 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - November 15, 2023 Category: Dermatology Authors: Aikaterini Tsiogka Efthymia Agiasofitou Antonios Tsimpidakis George Kontochristopoulos Alexander Stratigos Stamatios Gregoriou Source Type: research
Management of primary plantar hyperhidrosis with botulinum toxin type A: A retrospective case series of 129 patients
CONCLUSIONS: The results of this retrospective study suggest that BoNT-A is an effective and safe treatment option for PPH.PMID:37964488 | DOI:10.1111/ajd.14188 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - November 15, 2023 Category: Dermatology Authors: Aikaterini Tsiogka Efthymia Agiasofitou Antonios Tsimpidakis George Kontochristopoulos Alexander Stratigos Stamatios Gregoriou Source Type: research
Management of primary plantar hyperhidrosis with botulinum toxin type A: A retrospective case series of 129 patients
CONCLUSIONS: The results of this retrospective study suggest that BoNT-A is an effective and safe treatment option for PPH.PMID:37964488 | DOI:10.1111/ajd.14188 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - November 15, 2023 Category: Dermatology Authors: Aikaterini Tsiogka Efthymia Agiasofitou Antonios Tsimpidakis George Kontochristopoulos Alexander Stratigos Stamatios Gregoriou Source Type: research
Switching from onabotulinum toxin A to abobotulinum toxin A for treating detrusor overactivity in spinal cord injured patient, does it really work?
CONCLUSION: Switching from OTA to ATA toxin for IDI in the treatment of detrusor overactivity after spinal cord injury have long-term efficacy for a limited number of patients but may delay the need for surgery.PMID:37550178 | DOI:10.1016/j.purol.2023.07.007 (Source: Progres en Urologie)
Source: Progres en Urologie - August 7, 2023 Category: Urology & Nephrology Authors: C Le Roy C Lef èvre L Lepoittevin B Reiss M Le Fort J Rigaud B Perrouin-Verbe M-A Perrouin-Verbe Source Type: research
